Living with Inflammatory Bowel Disease (IBD) can feel like a daily battle against an unpredictable opponent. One day might bring a semblance of normalcy, while the next could be marked by debilitating pain, fatigue, and digestive distress. For many people globally, this chronic condition can impact various aspects of daily life, requiring ongoing management of symptoms, diet, and overall health.
Despite its widespread prevalence, IBD often remains overshadowed by other chronic illnesses, leaving those affected to navigate a challenging and often isolating journey. The unpredictable nature of IBD means that individuals must constantly manage symptoms that can flare up without warning, leading to frequent doctor visits, strict dietary restrictions, and major lifestyle adjustments.
The relentless cycle of managing this condition can result in emotional stress, anxiety, and social isolation. The physical discomfort and fatigue associated with IBD can make it difficult to maintain employment, engage in social activities, and pursue hobbies, all of which can severely impact overall well-being. Evinature, a healthtech company, is addressing these challenges with a new strategy for managing inflammatory bowel disease.
Addressing the Unmet Needs in IBD Treatment
Evinature is addressing the challenges of IBD with a new approach that incorporates natural, integrative therapies combined with recent scientific insights. Central to Evinature’s strategy is the CurQD® Protocol, developed at Sheba Medical Center by Professor Shomron Ben-Horin and Nir Salomon. This protocol aims to offer a holistic approach to managing IBD by targeting the underlying causes of inflammation with natural compounds, supported by clinical research.
The CurQD® Protocol is designed to explore the root causes of inflammation, using natural substances that have been studied in clinical trials. This approach is grounded in current nutraceutical research and aims to provide treatments that are both effective and safe. For patients who have found conventional pharmaceutical treatments inadequate, the CurQD® Protocol offers an alternative that may support their management of IBD by focusing on its fundamental mechanisms.
Innovation in Post-Diverticulitis Syndrome (PDS) Care
In addition to its initiatives with IBD, Evinature is addressing Post-Diverticulitis Syndrome (PDS), a condition often overlooked or misdiagnosed, which can prolong patient discomfort. Evinature’s DivertX is a natural treatment aimed at PDS, focusing on the inflammation and digestive symptoms that can persist following an episode of diverticulitis.
PDS can be confused with Irritable Bowel Syndrome (IBS), sometimes leading to less effective treatments and frequent relapses. In collaboration with Sheba Medical Center, Evinature has developed a PDS disease index to help improve diagnostic precision and patient care. This effort is part of Evinature’s broader commitment to enhancing gastrointestinal health and providing patients with more accurate diagnoses and tailored care.
Driving Forward Through Collaboration
Evinature’s initiatives are supported through collaborations with prominent organizations and researchers in gastroenterology. At the recent IBD Innovate Conference, Evinature introduced the CurQD® Protocol, discussing its approach to IBD management. The company’s affiliations with groups like the Crohn’s & Colitis Foundation (CCF) illustrate its involvement in enhancing natural medicine by working cooperatively with others in the field.
Such partnerships are important for advancing the development of new treatment options and improving patient care. By working alongside leading researchers, patient advocates, and business leaders, Evinature contributes to innovations in gastrointestinal health, aiming to improve understanding and treatment of conditions like PDS and IBD.
A New Era in Gastrointestinal Health
Evinature is committed to integrating natural medicine and scientific research in managing chronic gastrointestinal conditions. The CurQD® Protocol and DivertX represent initial steps toward what the company envisions as a shift toward holistic, patient-centered care. Evinature emphasizes a combination of patient well-being and thorough research in its approach to treating conditions like PDS and IBD.
As the healthcare environment evolves, Evinature’s approaches aim to support people living with these challenging conditions. The company focuses on transparency, community involvement, and scientific diligence as it seeks to influence the management of chronic gastrointestinal diseases.
Disclaimer: “The products discussed in this article have not been evaluated by the Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. The information provided is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.”
Published by: Nelly Chavez
